自体造血干细胞移植治疗NK/T细胞淋巴瘤的临床研究

摘要

Objective:To analyze retrospectively the results of treatment with APBSCT for NK/T - cell lymphoma. Methods:To conduct a review of NK/T cell lymphoma patients who underwent APBSCT from March 2001 to April 2010,all of 15 patients received the high-dose chemotherapy with vincristine, cytarabine,etoposide, mitoxantrone, Semustine, cyclophosphamide, and total body irradiation (TBI). Results: After a median follow - up of 49 ( 15 -120)months,the overall survival and disease - free survival rates after transplantation were 93. 3% and 86. 7% ,respectively. Two cases( 13.3% ) relapsed: one cases (ID phase, PR before transplantation) relapsed 7 months after transplantation;the other cases(IV ,PR) relapsed 3 months after transplantation and died. Conclusion; APBSCT may be an effective and safe treatment for NK/T cell lymphoma,however there was minimal durable benefit in patients with Ⅲ or IV phase.%目的:观察自体造血干细胞移植治疗NK/T细胞瘤鼻型的疗效.方法:2001年3月-2010年4月行AHST治疗NK/T细胞淋巴瘤15例,所有患者均采用VAEMMC+ TBI预处理方案.结果:随访中位时间49月(15-120月),14例患者(93.3％)存活,其中无病存活13例(86.7％)；2(13.3％)例复发:1例移植前为Ⅲ期PR,移植后7个月复发；1例Ⅳ期PR于移植后3个月复发并死亡.结论:自体造血干细胞移植治疗NK/T细胞淋巴瘤安全有效,但对于Ⅲ、Ⅳ期患者疗效差.